Zobrazeno 1 - 10
of 104
pro vyhledávání: '"C. Kreft-Jais"'
Publikováno v:
British Journal of Dermatology. 166:1333-1341
Summary Background The question of quantitative and qualitative differences between adverse drug reactions (ADRs) to tetracyclines was raised many years ago, especially for minocycline and doxycycline. Objectives To assess and compare ADRs related to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36896a2e2bbd22b890db1653cd31f971
https://doi.org/10.1111/j.1365-2133.2012.10845.x
https://doi.org/10.1111/j.1365-2133.2012.10845.x
Autor:
Evelyne Jacqz-Aigrain, Véronique Lamarque, E. Autret-Leca, L. Becquemont, M.-J. Boutroy, P. Carlier, A. Castot, C. Cornu, C. Damase-Michel, J.-P. Demarez, E. Dohin, M. Gersberg, C. Kreft-Jais, H. Le Louet, F. Meillier, J.-L. Parier, G. Pons, D. Subtil, T. Vial
Publikováno v:
Therapies. 61:297-304
Data required to asses the risk of a new drug regarding the normal course of pregnancy as well as embryo, fetal and neonate development, are often missing when a new product is launched. In such a situation, a risk management plan is to be developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c61ab067ec4d86409625c8a8de179ace
https://doi.org/10.2515/therapie:2006057
https://doi.org/10.2515/therapie:2006057
Autor:
Evelyne Jacqz-Aigrain, Véronique Lamarque, E. Autret-Leca, L. Becquemont, M.-J. Boutroy, P. Carlier, A. Castot, C. Cornu, C. Damase-Michel, J.-P. Demarez, E. Dohin, M. Gersberg, C. Kreft-Jais, H. Le Louet, F. Meillier, J.-L. Parier, G. Pons, D. Subtil, T. Vial
Publikováno v:
Therapies. 61:287-295
Resume Les donnees evaluant le risque d’un nouveau produit sur le deroulement normal de la grossesse et le developpement de l’embryon, du fœtus et du nouveau-ne sont le plus souvent manquantes lors de la mise sur le marche d’un nouveau produit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cb12ea5cd9cf3d99dd3e6f1c0bcd308
https://doi.org/10.2515/therapie:2006056
https://doi.org/10.2515/therapie:2006056
Autor:
F. J. De Abajo, Dolores Montero, C. Kreft-Jais, R. Coulson, J. L. Monteagudo, Nicholas Moore, A. Biron
Publikováno v:
Pharmacoepidemiology & Drug Safety. 3:157-162
The development of telematic exchange of information in pharmacovigilance has as a consequence the necessary development of the messages used to transmit the information. The first of these messages is the one used to transmit information on individu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6557bcc87345faba2a5056adda0628a
https://doi.org/10.1002/pds.2630030306
https://doi.org/10.1002/pds.2630030306
Autor:
R. Palop, C. Kreft-Jais, F. J. De Abajo, A. Biron, R. Coulson, Nicholas Moore, Dolores Montero
Publikováno v:
Pharmacoepidemiology & Drug Safety. 3:151-155
Pharmacovigilance is a field where communication is paramount. Information, such as single case reports, is transferred from health professionals to National Regulatory Administrations and between administrations and industry. The cumulation of repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2227dd1942b6e21b3b0d3ec4f126c400
https://doi.org/10.1002/pds.2630030305
https://doi.org/10.1002/pds.2630030305
Autor:
K. Wigglesworth, Dolores Montero, J. L. Monteagudo, C. Kreft-Jais, F. J. De Abajo, A. Biron, R. Coulson, Nicholas Moore, J. L. Zabala
Publikováno v:
Pharmacoepidemiology & Drug Safety. 3:163-167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2e8c9b511af35fd149f6c696c126ff1
https://doi.org/10.1002/pds.2630030307
https://doi.org/10.1002/pds.2630030307
Publikováno v:
Therapie. 57(3)
The academic interest for pharmacovigilance appears to be very low, because of the judged weakness of a "significant" relationship between drug utilisation and pathological events. We have tried to collect the relevant surveys of the French pharmacov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fa0d252f29c79bcc74b60098461e7500
https://pubmed.ncbi.nlm.nih.gov/12422541
https://pubmed.ncbi.nlm.nih.gov/12422541
Publikováno v:
Therapie. 50(6)
The French drug surveillance (pharmacovigilance) system is based on a network of 31 regional centres which receive adverse drug reaction (ADR) reports from health professionals and are drug information centers. Cases are entered into a common databas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1dbafa42e1d46ddcbbd82e5137151c10
https://pubmed.ncbi.nlm.nih.gov/8745956
https://pubmed.ncbi.nlm.nih.gov/8745956
Publikováno v:
Therapie.
The pharmacological class of calcium channel antagonists (CCA) is, with beta-adrenergic antagonists, diuretics, converting enzyme inhibitors and alpha-adrenergic antagonists, one of the first line monotherapies of essential hypertension, according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::19aa519d1117b587905fed39c3978a3d
https://pubmed.ncbi.nlm.nih.gov/8091351
https://pubmed.ncbi.nlm.nih.gov/8091351
Publikováno v:
La Revue du praticien. 42(20)
Novel angiotensin converting enzyme inhibitors (ACE inhibitors) have recently been commercialized and the question arises whether differences in pharmacodynamic and pharmacokinetic properties should lead to specific therapeutic choices. To our knowle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c559d97cc2c952edb30e8ca9bf457aeb
https://pubmed.ncbi.nlm.nih.gov/1299936
https://pubmed.ncbi.nlm.nih.gov/1299936